Institute of Nuclear Medicine, University College London, London, UK.
Br J Radiol. 2014 Jan;87(1033):20130464. doi: 10.1259/bjr.20130464. Epub 2013 Nov 14.
Evaluation of the molecular processes responsible for disease pathogenesis and progression represents the new frontier of clinical radiology. Multimodality imaging lies at the cutting edge, combining the power of MRI for tissue characterization, microstructural appraisal and functional assessment together with new positron emission tomography (PET) tracers designed to target specific metabolic processes. The recent commercial availability of an integrated clinical whole-body PET-MRI provides a hybrid platform for exploring and exploiting the synergies of multimodal imaging. First experiences on the clinical and research application of hybrid PET-MRI are emerging. This article reviews the rapidly evolving field and speculates on the potential future direction.
评估导致疾病发病机制和进展的分子过程代表了临床放射学的新前沿。多模态成像处于前沿,将 MRI 的组织特征、微观结构评估和功能评估能力与旨在针对特定代谢过程的新型正电子发射断层扫描 (PET) 示踪剂相结合。最近,临床全身体积 PET-MRI 的商业化提供了一个用于探索和利用多模态成像协同作用的混合平台。关于该混合 PET-MRI 的临床和研究应用的初步经验正在出现。本文综述了这一快速发展的领域,并对未来的潜在方向进行了推测。